BRIC (BoRdeaux Institute of onCology), UMR1312, INSERM, University of Bordeaux, 33000 Bordeaux, France.
Institute of Biomedical Sciences of Abel Salazar, Porto University, 4050-313 Porto, Portugal.
Genes (Basel). 2023 Feb 8;14(2):439. doi: 10.3390/genes14020439.
As a major cancer hallmark, there is a sustained interest in understanding the telomerase contribution to carcinogenesis in order to therapeutically target this enzyme. This is particularly relevant in primary cutaneous T-cell lymphomas (CTCL), a malignancy showing telomerase dysregulation with few investigative data available. In CTCL, we examined the mechanisms involved in telomerase transcriptional activation and activity regulation. We analyzed 94 CTCL patients from a Franco-Portuguese cohort, as well as 8 cell lines, in comparison to 101 healthy controls. Our results showed that not only polymorphisms (SNPs) located at the promoter of human telomerase reverse transcriptase ( gene (rs2735940 and rs2853672) but also an SNP located within the coding region (rs2853676) could influence CTCL occurrence. Furthermore, our results sustained that the post-transcriptional regulation of contributes to CTCL lymphomagenesis. Indeed, CTCL cells present a different pattern of spliced transcripts distribution from the controls, mostly marked by an increase in the β+ variants proportion. This increase seems to be associated with CTCL development and progression. Through splicing transcriptome modulation with shRNAs, we observed that the decrease in the α-β+ transcript induced a decrease in the cell proliferation and tumorigenic capacities of T-MF cells in vitro. Taken together, our data highlight the major role of post-transcriptional mechanisms regulating telomerase non canonical functions in CTCL and suggest a new potential role for the α-β+ transcript variant.
作为癌症的一个主要标志,人们一直有兴趣了解端粒酶在致癌作用中的贡献,以便能够对这种酶进行治疗性靶向。这在原发性皮肤 T 细胞淋巴瘤(CTCL)中尤为重要,这种恶性肿瘤表现出端粒酶失调,但可用的研究数据很少。在 CTCL 中,我们研究了端粒酶转录激活和活性调节所涉及的机制。我们分析了来自法葡队列的 94 名 CTCL 患者以及 8 个细胞系,并与 101 名健康对照进行了比较。我们的研究结果表明,不仅位于人类端粒酶逆转录酶(基因)启动子处的多态性(SNP)(rs2735940 和 rs2853672),而且位于编码区的 SNP(rs2853676)也可能影响 CTCL 的发生。此外,我们的研究结果还表明,的转录后调控有助于 CTCL 的淋巴瘤发生。事实上,CTCL 细胞呈现出与对照组不同的剪接转录本分布模式,主要表现为β+变体比例增加。这种增加似乎与 CTCL 的发展和进展有关。通过 shRNA 对剪接转录组进行调节,我们观察到α-β+转录本的减少导致 T-MF 细胞体外增殖和致瘤能力下降。总之,我们的数据强调了调节端粒酶非典型功能的转录后机制在 CTCL 中的主要作用,并提示α-β+转录本变体具有新的潜在作用。